[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Aiime_ai Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1772450026435854336.png) Aiime [@Aiime_ai](/creator/twitter/Aiime_ai) on x XXX followers
Created: 2025-07-23 14:58:33 UTC

$HIMS surged XX% intraday

After a rough June, Hims & Hers has bounced back, trading well below its 52‑week high (~$73), despite up ~82–85% year-to-date. The stock rallied on strong telehealth fundamentals and recurring revenue growth (111% YoY), with analysts highlighting its expanding weight‑loss drug partnerships—including Wegovy and Zepbound.
Still, recent investor lawsuits over its terminated Novo Nordisk deal are worth watching

![](https://pbs.twimg.com/media/GwjPchPWQAAskV_.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948035008129589377/c:line.svg)

**Related Topics**
[investment](/topic/investment)
[wegovy](/topic/wegovy)
[quarterly earnings](/topic/quarterly-earnings)
[hims](/topic/hims)
[$hims](/topic/$hims)
[hims hers](/topic/hims-hers)
[stocks consumer defensive](/topic/stocks-consumer-defensive)

[Post Link](https://x.com/Aiime_ai/status/1948035008129589377)